Highest-materiality recent filing
Shareholders approved removal of supermajority voting requirements (24.3M for, 95k against); effective May 18, 2026.
Jesse Geiger to resign as President effective May 31, 2026; not due to disagreement.
Medpace reports Q4/FY2025 results; specific figures unavailable from filing
Press release issued Feb 9, 2026 for quarter and year ended Dec 31, 2025.
Medpace reports Q3 2025 earnings; press release unavailable for detail extraction
Issued press release on October 22, 2025 announcing financial results for three and nine months ended September 30, 2025.
Medpace reduces credit line to $10M; Q2 2025 earnings announced, figures not provided
Amendment No. 9 to credit facility reduces line of credit to $10M, executed July 17, 2025.
Elected August J. Troendle (21.2M for) and Dani S. Zander (25.9M for) as Class III directors.
Board approved $1.0B increase to stock repurchase program; timing based on market conditions.
Medpace extends revolving credit facility expiration to March 31, 2026
Amendment No. 7 extends the revolving credit note expiration date to March 31, 2026, representing a one-year extension.
Medpace reports Q4/FY24 earnings (no specifics shown) and boosts buyback by $600M
Issued press release for Q4 and FY2024 results; no financial figures included in filing.
Medpace reports Q3 2024 results; details not available in extracted exhibit text
Press release dated October 21, 2024, issued under Item 2.02.
Medpace Holdings announces Q2 2024 financial results on July 22, 2024
Medpace Holdings issued a press release on July 22, 2024, reporting financial results for the three and six months ended June 30, 2024.
Medpace director Ashley Keating resigns; Dr. Dani Zander elected to board
Ashley M. Keating resigned from the Board effective June 30, 2024, with no disagreement on operations, policies, or practices.
Medpace shareholders approve board declassification; annual director elections start 2025
Stockholders approved amendment to phase out classified board; directors elected annually beginning at 2025 annual meeting.
Medpace reports Q1 2024 results; exhibit not provided, no specific data available
Press release filed as Exhibit 99.1 for three months ended March 31, 2024.
Medpace reduces revolving credit facility from $150M to $10M, extends to March 2025
Line of credit reduced to $10M from $150M; expiration extended to March 31, 2025.
On June 28, 2024, Ashley M. Keating, a member of the Board of Directors (the “Board”) of Medpace Holdings, Inc. (the “Company”) notified the Company of her resignation, effective as of June 30, 2024.
The Board of the Company following a recommendation from the independent directors of the Board, unanimously approved that Dr. Dani S. Zander be elected to fill the Class III director vacancy on the Board of the Company, effective July 1, 2024
Max materiality 0.70 · Median 0.50 · Most common event other_material